Jula Inrig, M.D.

Chief Medical Officer
Jula Inrig, M.D.

Having cared for people suffering with rare diseases, I am passionate about discovering, developing and delivering innovative therapies to bring hope and healing to patients and their families.

Jula Inrig, M.D., joined Travere Therapeutics in January 2022 as the company’s chief medical officer. In this role, she is responsible for overseeing the company’s medical functions, clinical development, and clinical operations as well as drug safety/pharmacovigilance.

She brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution as well as global regulatory engagement. Prior to joining Travere, Dr. Inrig served as Global Head of the Renal Center of Excellence at IQVIA. While at IQVIA, Dr. Inrig was instrumental in the design, execution and strategy of clinical trials leading to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals in autosomal dominant polycystic kidney disease (ADPKD), and diabetic kidney disease. She was also responsible for the execution of more than 45 clinical trials across 50 countries, enrolling over 25,000 patients, including pivotal phase 3 trials in FSGS, IgAN and lupus nephritis. In addition to her roles at IQVIA, Dr. Inrig served as an inaugural member of the board for the Kidney Health Initiative, a public-private partnership with the FDA, founded with the goal of improving the development of therapies for patients with kidney disease. Dr. Inrig has also served in advisory roles for national societies and their guidelines including the American Society of Nephrology, the National Kidney Foundation, and the American Heart Association.

Dr. Inrig has been recognized by PharmaVOICE magazine as one of the “100 Most Inspiring People” in the life sciences industry, by Women We Admire as one of the “Top 50 Women Leaders of Los Angeles,” and by the Healthcare Businesswomen’s Association as a Luminary award winner.

Dr. Inrig is board certified in nephrology and internal medicine and serves on the faculty at the University of California, Irvine, and as an adjunct in the Department of Medicine at the Duke University School of Medicine. Dr. Inrig received her M.D. from Loma Linda University and completed her internal medicine residency, her nephrology fellowship and obtained a Master of Health Science at Duke University. Dr. Inrig holds a B.A. from California State University, Sacramento.